8-K: DBV Technologies Receives Second Extension to Regain Nasdaq Compliance, Transfers to Capital Market

DBV Technologies has been granted a second extension until December 16, 2024, to regain compliance with Nasdaq's minimum bid price rule and will transfer its listing to the Nasdaq Capital Market.

Summary

• DBV Technologies failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, which is a violation of Nasdaq's Continued Listing Rule 5550(a)(2).
• The company was initially given 180 days, until June 17, 2024, to regain compliance.
• On June 18, 2024, Nasdaq granted DBV Technologies a second 180-day extension, until December 16, 2024, to meet the minimum bid price requirement.
• The company's American Depositary Shares (ADSs) will be transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective June 20, 2024.
• To regain compliance, DBV Technologies must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• If the company fails to regain compliance by December 16, 2024, Nasdaq may delist the ADSs, but DBV Technologies can request a hearing to appeal the decision.

Sentiment

Score: 3

Explanation: The document indicates a significant issue with the company's share price and the risk of delisting, which is a negative signal for investors. The second extension provides some hope, but the underlying problem remains.

Positives

• DBV Technologies has been granted a second chance to regain compliance with Nasdaq's listing requirements.
• The transfer to the Nasdaq Capital Market is not expected to impact trading of the ADSs.

Negatives

• DBV Technologies has failed to maintain the minimum bid price of $1.00 per share for an extended period.
• The company faces the risk of delisting if it cannot regain compliance by December 16, 2024.

Risks

• There is no guarantee that DBV Technologies will be able to regain compliance with the minimum bid price requirement.
• The company could be delisted from Nasdaq if it fails to meet the compliance deadline.
• Delisting could negatively impact the company's ability to raise capital and its share price.

Future Outlook

DBV Technologies will use all reasonable efforts to achieve compliance with the minimum bid price rule, but there is no assurance that they will be successful.

Industry Context

This announcement is not uncommon for companies that have experienced a decline in their share price. Many companies face similar challenges in maintaining compliance with listing requirements.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, can face challenges in maintaining share price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Agenus Inc. (AGEN) and Cassava Sciences, Inc. (SAVA) have also faced similar compliance issues with Nasdaq, highlighting the volatility and risk associated with biotech stocks.
• The transfer to the Nasdaq Capital Market is a common step for companies seeking more time to regain compliance, as it often has less stringent requirements than the Global Select Market.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• DBV Technologies must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days before December 16, 2024.
• The company may request a hearing before the Nasdaq Hearings Panel if they fail to regain compliance and receive a delisting notice.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, DBV Technologies, listing, ADS, DBVT